Saturday, May 21, 2022
No Result
View All Result
Medical Finance
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
  • Home
  • News
  • Interviews
  • Mediknowledge
  • Insights From Industry
  • Thought Leaders
  • Coronavirus
  • Whitepapers
No Result
View All Result
Medical Finance
No Result
View All Result
Home Coronavirus

Convalescent antibodies do not enhance SARS-CoV-2 infection

by Medical Finance
in Coronavirus
Study: Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. Image Credit: Corona Borealis Studio/Shutterstock
9
SHARES
99
VIEWS
Share on FacebookShare on Twitter

A recent study published in PLOS ONE investigated whether antibodies enhance severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection.

Study: Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. Image Credit: Corona Borealis Studio/Shutterstock
Study: Anti-SARS-CoV-2 IgG and IgA antibodies in COVID-19 convalescent plasma do not enhance viral infection. Image Credit: Corona Borealis Studio/Shutterstock

In the early coronavirus disease 2019 (COVID-19) pandemic period, COVID-19 convalescent plasma (CCP) was recommended as a passive immunization therapy for patients with acute infection. As such, it was one of the few therapeutic options available initially; while the treatment produced positive results to some extent, its efficacy is poorly understood.

Clinical efficacy is determined by the neutralization antibody titers and resultant neutralization activity of the CCP unit. Previously, the authors of this study reported that quantifying antibodies directed at SARS-CoV-2 spike (S) protein’s receptor-binding domain (RBD) was a better proxy for SARS-CoV-2 neutralization.

Despite the promising results of CCP, it remains to be investigated if anti-S protein antibodies cause adverse events in CCP recipients; specifically, antibody-dependent enhancement (ADE) of infection that might enhance viral replication and cause subsequent infections. ADE possibility is high when SARS-CoV-2 reinfection or vaccine-breakthrough event occurs.

The current study measured anti-SARS-CoV-2 S protein antibodies of the IgA, IgM, and IgG isotypes and assessed the role of ADE due to anti-S antibodies in COVID-19 infection. The researchers developed an infectivity assay based on retrovirus pseudotypes to evaluate neutralizing titers of CCP units in cells expressing only angiotensin-converting enzyme-2 (ACE2), the human receptor for SARS-CoV-2, or in combination with either Fc gamma receptor II (FcγRIIA) or Fc alpha receptor (FcαR).

Serum and plasma samples were obtained from 90 CCP donors. The half-maximal inhibitory concentration (IC50) values ranged from <8 – 581.4, highlighting the varying degrees of neutralization responses. Moreover, total Ig titers and anti-nucleocapsid (anti-N) IgG antibodies varied among the CCP donors.

The authors noted variations in total anti-S protein responses among the donors, and a correlation of anti-RBD and anti-S protein antibodies (of IgG isotype) to the neutralization potential of CCP. Between April–August 2020, 48 patients received CCP therapy; of these, four were excluded because they were hospitalized with a non-COVID-19 life-threatening illness. Mechanical ventilation and intubation were used as detrimental markers assessing disease progression, and sustained respiratory improvement was used as a recovery marker.

Most patients showed sustained respiratory improvement at an average of 7.9 days post-admission. Seven patients (16%) died post-CCP transfusion while 37 were alive. In the early period of the study, patients were admitted before the availability of CCP units. They were on average provided with CCP nine days after admission, and in the later weeks, patients were transfused with plasma within two days.

The antibodies transferred from the CCP donors were assessed to ascertain if they were non-detrimental to recipients. To this end, plasma and serum samples of the 90 donors were assayed for ADE of infection of retroviral pseudotypes. They assessed the neutralization of murine leukemia virus (MLV) particles pseudotyped with the S protein of SARS-CoV-2 in cells that expressed ACE2 alone or with Fc receptors (ACE2 and FcαR-, and ACE2 and FcγRIIA-expressing cells). An increase in IC50 values in the presence of Fc receptors was considered ADE of pseudovirions. No differences were observed in individual samples’ IC50 values, indicating that S-protein mediated ADE was absent at least when Fc receptors were present. Moreover, IgA, IgM, and IgA titers were quantified using an in-house antibody-capture enzyme-linked immunosorbent assay (ELISA). Titers of anti-S IgG antibodies were higher than that of IgM or IgA subtypes, and IgA and IgM titers did not differ significantly from each other.

Conclusions

The authors noted the absence of Fc receptor-mediated ADE of SARS-CoV-2 infection during the use of polyclonal antibodies from CCP donors. The neutralizing ability of antibodies from convalescents varied from one individual to other. Most antibodies against the S protein were of IgG class with lower IgM and IgA subtypes. Given the low titers of anti-S IgM and IgA antibodies, these were not found to enhance SARS-CoV-2 infection through their respective Fc receptors. However, ADE of SARS-CoV-2 infection may occur in vivo through a different mechanism.

Moreover, the samples were collected before any SARS-CoV-2 variant of concern (VOC) emerged, and it is possible that individuals with prior non-VOC infection could experience ADE if they get reinfected with a VOC. In conclusion, the present work reported the safety of antibody-based therapies (vaccines and CCP) and showed that using anti-S protein antibodies does not enhance SARS-CoV-2 infection.

Total
0
Shares
Share 0
Tweet 0
Pin it 0
Share 0
Medical Finance

Medical Finance

Related Posts

Study: Estimating the relative proportions of SARS-CoV-2 strains from wastewater samples. Image Credit: Nhemz/Shutterstock

Quantification of SARS-CoV-2 variants in wastewater samples

by Medical Finance
May 20, 2022
0

In a recent study posted to the pre-print medRxiv* server, a team of researchers introduced a novel method to estimate...

Study: The Effects of SARS-CoV-2 Infection on Female Fertility: A Review of the Literature. Image Credit: NIAID

How does SARS-CoV-2 infection impact female fertility?

by Medical Finance
May 20, 2022
0

In a recent study published in the journal International Journal of Environmental Research and Public Health, a team of researchers...

Study: Limited cross-variant immunity after infection with the SARS-CoV-2 Omicron variant without vaccination. Image Credit: PHOTOCREO Michal Bednarek/Shutterstock

Study finds Omicron infection effectively induces immunity against itself and enhances protection against other variants in vaccinated individuals

by Medical Finance
May 20, 2022
0

In a recent study posted to the medRxiv* preprint server, researchers investigated the effectiveness of the severe acute respiratory...

Study: Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study. Image Credit: Viacheslav Lopatin / Shutterstock

Recipients of inactivated COVID-19 vaccine (CoronaVac) can be successfully boosted with different vaccines

by Medical Finance
May 20, 2022
0

Heterologous boosting of the whole-virion SARS-CoV-2 vaccine (CoronaVac, Sinovac) results in more robust immune responses than homologous boosting and could...

Study: Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time. Image Credit: Maria Sbytova / Shutterstock.com

Adults and children have similar neutralizing antibody responses to SARS-CoV-2 infection

by Medical Finance
May 20, 2022
0

In a recent study published on the medRxiv* preprint server, researchers describe the kinetics of severe acute respiratory syndrome coronavirus...

OBSERVATIONAL STUDY Neurologic Manifestations of Severe Acute Respiratory Syndrome Coronavirus 2 Infection in Hospitalized Patients During the First Year of the COVID-19 Pandemic. Image Credit: Donkeyworx / Shutterstock

Approximately 13% of hospitalized COVID patients have serious neurologic symptoms

by Medical Finance
May 20, 2022
0

It has been established that the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causes dysfunction throughout the body, including the...

Next Post
Bacterial biofilms use a developmental patterning mechanism seen in plants and animals

Rising temperatures lead to increased prevalence of Vibrio bacteria in UK waters

Study: Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. Image Credit: creativeneko/Shutterstock

Effectiveness of prior infection in preventing reinfection with Omicron and other SARS-CoV-2 variants in Qatar

0 0 votes
Article Rating
Subscribe
Login
Notify of
guest
guest
0 Comments
Inline Feedbacks
View all comments

Support

  • Contact
  • Disclaimer
  • Home
  • Privacy Policy
  • Terms And Conditions

Categories

  • Coronavirus
  • Insights From Industry
  • Interviews
  • Mediknowledge
  • News
  • Thought Leaders
  • Whitepapers

More News

  • Study: Evaluation of a Rapid and Accessible RT-qPCR Approach for SARS-CoV-2 Variant of Concern Identification. Image Credit: anyaivanova/Shutterstock
    Impact of rapid and comprehensive RT-qPCR for detecting SARS-CoV-2 variants of concern
  • Study: Does having a cat in your house increase your risk of catching COVID-19? Image Credit: TanyaPhOtOgraf
    Study finds low-risk of spillover SARS-CoV-2 infection from domestic cats
  • Home
  • Privacy Policy
  • Contact
  • Disclaimer
  • Terms And Conditions

© 2022 Medical Finance - Latest Financial and Business News

No Result
View All Result
  • Interviews
  • Mediknowledge
  • News
  • Insights From Industry
  • Coronavirus
  • Thought Leaders
  • Whitepapers
wpDiscuz
0
0
Would love your thoughts, please comment.x
()
x
| Reply